Prospective, multicenter observational study of an integrated AI system with live monitoring to support early breast cancer detection.

Project: Industrial Research & DevelopmentIndustrial Collaboration

Project Details

Description

The Vara software helps to assess compatible digital or digitized images of the human breast with regard to the presence or absence of cancer findings using mathematical methods or artificial intelligence (AI). Vara was developed by MX Health Care and successfully certified as a European Class IIb medical device in September 2019. Vara supports the creation of machine-readable medical reports. The software is intended for the detection of breast cancer (ICD C50) in an approved mammography screening unit. UKSH and MXH are jointly conducting a prospective observational study with the project title "A prospective, multicenter observational study of an integrated AI system with live monitoring to support breast cancer screening (short: PRAIM study)". The aim is to evaluate the detection rates for breast cancer in mammography screening. It is expected that AI can provide useful support for breast cancer detection. The study is expected to run from January 2022 up to April 2025.
Short titlePRAIM-Studie
AcronymPRAIM
StatusActive
Effective start/end date01.02.2230.04.25

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being
  • SDG 9 - Industry, Innovation, and Infrastructure

Research Areas and Centers

  • Research Area: Center for Population Medicine and Public Health (ZBV)
  • Centers: Center for Artificial Intelligence Luebeck (ZKIL)

DFG Research Classification Scheme

  • 205-02 Public Health, Health Services Research and Social Medicine